CompletedNot Applicable

MRS to Determine Neuroinflammation and Oxidative Stress in MPS I

United States30 participantsStarted 2018-11-01

Plain-language summary

Neuroinflammation and oxidative stress have been shown to be present in persons with mucopolysaccharidosis type I (MPS I), but their effect on disease severity and disease progression is unknown. The investigator intends to employ brain magnetic resonance spectroscopy (MRS), a non-invasive technique, along with analysis of neuroinflammation and oxidative stress biomarkers in the blood, to measure and determine the level of oxidative stress and neuroinflammation, and their impact on clinical variability in MPS I patients.

Who can participate

Age range6 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of Hurler syndrome, OR Hurler-Scheie syndrome, OR Scheie syndrome
✓. 6 years of age or older at time of screening
✓. Absence of neurological disorder
✓. 6 years of age or older at time of screening

Exclusion criteria

✕. Any surgically implanted pacemaker
✕. Any indwelling electronic device, including programmable shunts
✕. Orthodontic braces, unless non-metallic
✕. Other implanted metal in the body other than titanium
✕. An inability or unwillingness to complete an MRI/MRS because of low cognitive function or behavioral dysregulation
✕. Pregnancy

What they're measuring

Brain Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy (MRI/MRS)

Timeframe: 1 day -Single encounter during an appointment which is set at time of study enrollment.

Trial details

NCT IDNCT03576729

SponsorUniversity of Minnesota

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-08-31

View on ClinicalTrials.gov More Mucopolysaccharidosis Type I trials